Judah Frommer
Stock Analyst at Morgan Stanley
(3.00)
# 1,506
Out of 4,761 analysts
179
Total ratings
58.02%
Success rate
5.2%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GLPG Galapagos NV | Downgrades: Underweight | $31 → $22 | $26.74 | -17.73% | 3 | Feb 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Underweight | $8 → $6 | $4.64 | +29.31% | 2 | Jan 13, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Equal-Weight | $31 | $27.52 | +12.65% | 1 | Nov 21, 2024 | |
| RGNX REGENXBIO | Assumes: Overweight | $22 | $7.27 | +202.61% | 1 | Nov 15, 2024 | |
| ACLX Arcellx | Maintains: Overweight | $81 → $106 | $63.75 | +66.27% | 2 | Nov 6, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | $35 | $13.00 | +169.23% | 1 | Oct 8, 2024 | |
| MURA Mural Oncology | Initiates: Overweight | $13 | $4.05 | +220.99% | 1 | Apr 4, 2024 | |
| PROK ProKidney | Assumes: Equal-Weight | $3 | $1.50 | +100.00% | 1 | Mar 7, 2024 | |
| JSPR Jasper Therapeutics | Reiterates: Outperform | $40 | $5.96 | +571.14% | 8 | Aug 14, 2023 | |
| ABOS Acumen Pharmaceuticals | Reiterates: Outperform | $13 | $1.39 | +835.25% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $31.12 | -3.60% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $8.33 | +176.11% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $50.69 | -1.36% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $106.28 | +32.67% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.39 | +835.25% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $1.99 | +352.26% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $18.57 | +18.47% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $11.63 | -39.81% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $3.85 | +107.79% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $12.56 | +266.24% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $1.82 | +284.62% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $12.84 | +328.35% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $81.06 | -43.25% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $81.85 | -40.13% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $1,035.03 | -64.25% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $70.10 | -55.78% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $73.22 | +3.80% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $76.69 | +137.32% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $74.96 | +42.74% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $96.78 | -1.84% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $20.55 | -12.41% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $85.92 | +35.01% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $101.49 | -62.56% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $143.32 | -84.65% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $65.06 | -46.20% | 9 | Apr 29, 2020 |
Galapagos NV
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $26.74
Upside: -17.73%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $4.64
Upside: +29.31%
Apellis Pharmaceuticals
Nov 21, 2024
Initiates: Equal-Weight
Price Target: $31
Current: $27.52
Upside: +12.65%
REGENXBIO
Nov 15, 2024
Assumes: Overweight
Price Target: $22
Current: $7.27
Upside: +202.61%
Arcellx
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $63.75
Upside: +66.27%
Bicara Therapeutics
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $13.00
Upside: +169.23%
Mural Oncology
Apr 4, 2024
Initiates: Overweight
Price Target: $13
Current: $4.05
Upside: +220.99%
ProKidney
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $1.50
Upside: +100.00%
Jasper Therapeutics
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $5.96
Upside: +571.14%
Acumen Pharmaceuticals
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.39
Upside: +835.25%
Aug 9, 2023
Reiterates: Outperform
Price Target: $30
Current: $31.12
Upside: -3.60%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $8.33
Upside: +176.11%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $50.69
Upside: -1.36%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $106.28
Upside: +32.67%
May 16, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.39
Upside: +835.25%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $1.99
Upside: +352.26%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $18.57
Upside: +18.47%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $11.63
Upside: -39.81%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $3.85
Upside: +107.79%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $12.56
Upside: +266.24%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $1.82
Upside: +284.62%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $12.84
Upside: +328.35%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $81.06
Upside: -43.25%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $81.85
Upside: -40.13%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $1,035.03
Upside: -64.25%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $70.10
Upside: -55.78%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $73.22
Upside: +3.80%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $76.69
Upside: +137.32%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $74.96
Upside: +42.74%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $96.78
Upside: -1.84%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $20.55
Upside: -12.41%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $85.92
Upside: +35.01%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $101.49
Upside: -62.56%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $143.32
Upside: -84.65%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $65.06
Upside: -46.20%